Knee cell products: separate osteoarthritis from focal cartilage defects
A knee injection, an expanded MSC product and an authorised chondrocyte implant are not interchangeable. Diagnosis, product and indication determine the evidence and legal route.
Start with the diagnosis. Generalised knee osteoarthritis, an isolated traumatic cartilage defect, meniscal disease and inflammatory arthritis are different problems. Imaging findings also do not determine symptoms or candidacy by themselves. An independent musculoskeletal clinician should confirm the diagnosis, severity, established options and treatment goal before a commercial product is discussed.
Identify the intervention exactly. Bone-marrow aspirate concentrate, adipose-derived preparations, culture-expanded MSCs, platelet products and autologous chondrocyte implants differ in composition, manufacturing and regulation. Results from one category cannot validate another, and the words “autologous” or “regenerative” do not establish safety, efficacy or authorisation.
Product-specific authorisation matters. FDA states that regenerative-medicine therapies have not been approved in the United States for orthopaedic conditions including osteoarthritis or knee pain. In the EU, Spherox is an authorised autologous chondrocyte ATMP for eligible symptomatic focal articular-cartilage defects up to 10 cm²; EMA states that it must not be used for primary generalised or advanced knee osteoarthritis. That narrow indication is not a general approval of MSC treatment for osteoarthritis.
Read studies by product, diagnosis and endpoint. Pain, function, rescue treatment, imaging and joint replacement are different outcomes. Check randomisation, comparator, masking, clinically meaningful change, missing data, adverse events and follow-up. A short-term average pain change does not prove cartilage regrowth or durable avoidance of surgery.
Ask for the exact product, source, manipulation, dose, route, manufacturer, release tests, regulator or trial reference, clinician, rehabilitation plan and complication pathway. Review the EMA Spherox record and FDA patient information, then compare the proposal with established non-operative and surgical care through an independent specialist.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.